L Beltrame
Overview
Explore the profile of L Beltrame including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pellegrino B, Capoluongo E, Bagnoli M, Arenare L, Califano D, Scambia G, et al.
ESMO Open
. 2025 Jan;
10(1):104091.
PMID: 39754985
Background: Ovarian cancer (OvC) constitutes significant management challenges primarily due to its late-stage diagnosis and the development of resistance to chemotherapy. The standard treatment regimen typically includes carboplatin and paclitaxel,...
2.
Capoluongo E, Pellegrino B, Arenare L, Califano D, Scambia G, Beltrame L, et al.
ESMO Open
. 2022 Sep;
7(5):100585.
PMID: 36156447
Background: The detection of homologous recombination deficiency (HRD) can identify patients who are more responsive to platinum and poly ADP ribose polymerase inhibitors (PARPi). MyChoice CDx (Myriad) is the most...
3.
Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, et al.
BMC Cancer
. 2017 Feb;
17(1):107.
PMID: 28166781
Background: Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive disease, that can be described as a member of the family of small round blue cell tumors....
4.
Mannarino L, Paracchini L, Craparotta I, Romano M, Marchini S, Gatta R, et al.
Pharmacogenomics J
. 2016 Dec;
18(1):56-63.
PMID: 27958379
This study was designed to investigate the mode of action of trabectedin in myelomonocytic leukemia cells by applying systems biology approaches to mine gene expression profiling data and pharmacological assessment...
5.
Calura E, Paracchini L, Fruscio R, DiFeo A, Ravaggi A, Peronne J, et al.
Ann Oncol
. 2016 May;
27(8):1511-9.
PMID: 27194815
Background: Clinical and pathological parameters of patients with epithelial ovarian cancer (EOC) do not thoroughly predict patients' outcome. Despite the good outcome of stage I EOC compared with that of...
6.
Petrillo M, Zannoni G, Beltrame L, Martinelli E, DiFeo A, Paracchini L, et al.
Ann Oncol
. 2016 Jan;
27(4):625-34.
PMID: 26782955
Background: Neoadjuvant chemotherapy (NACT) has been recognized as a reliable therapeutic strategy in patients with unresectable advanced epithelial ovarian cancer (EOC). The molecular events leading to platinum (Pt) response in...
7.
Beltrame L, Di Marino M, Fruscio R, Calura E, Chapman B, Clivio L, et al.
Ann Oncol
. 2015 Apr;
26(7):1363-71.
PMID: 25846551
Background: The majority of patients with stage III-IV epithelial ovarian cancer (EOC) relapse after initially responding to platinum-based chemotherapy, and develop resistance. The genomic features involved in drug resistance are...
8.
Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro S, Marchini S, et al.
Oncogene
. 2013 Nov;
33(44):5201-10.
PMID: 24213580
To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific subtypes, we have developed and characterized three MRCL xenografts,...
9.
Noe F, Polascheck N, Frigerio F, Bankstahl M, Ravizza T, Marchini S, et al.
Neurobiol Dis
. 2013 Aug;
59:183-93.
PMID: 23938763
We studied whether pharmacological blockade of the IL-1β-mediated signaling, rapidly activated in forebrain by epileptogenic injuries, affords neuroprotection in two different rat models of status epilepticus (SE). As secondary outcome,...
10.
Callegaro A, Spinelli R, Beltrame L, Bicciato S, Caristina L, Censuales S, et al.
Nucleic Acids Res
. 2006 Apr;
34(7):e56.
PMID: 16617143
Single nucleotide polymorphisms (SNPs) are often determined using TaqMan real-time PCR assays (Applied Biosystems) and commercial software that assigns genotypes based on reporter probe signals at the end of amplification....